A double-blind, randomized-controlled trial using a low dose of ketamine vs. active placebo in treating severe depression and suicide.
Not Applicable
- Conditions
- Major depression including unipolar and bipolar depression
- Registration Number
- JPRN-UMIN000033916
- Lead Sponsor
- Ministry of Science and Technology
- Brief Summary
Based on MADRS and HDRS scores, GEE models showed a significant difference in depressive symptoms between ketamine and midazolam groups (p=0.024 by MADRS, p=0.028 by HDRS) in the 2-week follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
1)Major medical conditions (e.g., head injury, epilepsy, severe renal diseases and cancer). 2)Other axis I psychiatric disorders such as schizophrenia, delusional disorder, organic brain syndrome, and dementia. 3)Pregnancy. 4)Substance abuse in previous 6 months. 5)Current use of NMDA receptor antagonist. 6)Attempt suicide in hospital.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method